Intraperitoneal slow released chemotherapy for advanced gastric cancer.
- Author:
Han LIANG
1
Author Information
1. Department of Gastrointestinal Cancer, Hospital of Tianjin Medical University, Tianjin, China. tjlianghan@126.com
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
administration & dosage;
therapeutic use;
Delayed-Action Preparations;
Humans;
Peritoneal Neoplasms;
drug therapy;
secondary;
Stomach Neoplasms;
drug therapy;
pathology
- From:
Chinese Journal of Gastrointestinal Surgery
2012;15(2):116-117
- CountryChina
- Language:Chinese
-
Abstract:
Regional lymph node recurrence is no longer the prominent concern regarding the prognosis of gastric cancer patients since the establishment of the standard D2 dissection procedure. Peritoneal metastasis has become the most prominent clinical problem. The treatment strategy for peritoneal metastasis includes intraperitoneal chemotherapy, hyperthermic intraperitoneal chemotherapy and intraperitoneal chemotherapy with drug delivery systems. Intraperitoneal chemotherapy has pharmacokinetic advantage when used in combination with drug delivery systems. Intraperitoneal chemotherapy with drug delivery systems is an effective treatment and prevention method.
